Expression of matrix metalloproteinases and their inhibitors in cords and nodules of patients with Dupuytren's disease

Archives of Orthopaedic and Trauma Surgery

Volumn 129, Issue 11, 2009, Pages 1453-1459

  Ulrich, Dietmar ^a   Ulrich, Franziska ^b   Piatkowski, Andrzej ^a   Pallua, Norbert ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b CARITAS KRANKENHAUS ST JOSEF   (Germany)

Author keywords

Dupuytren's disease; Fibrosis; Matrix metalloproteinases; Tissue inhibitors of metalloproteinases

Indexed keywords

GELATINASE A; GELATINASE B; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTICLE; CARPAL TUNNEL SYNDROME; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DOWN REGULATION; DUPUYTREN CONTRACTURE; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; MALE; PALMAR FASCIA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE STRUCTURE; UPREGULATION;

CASE-CONTROL STUDIES; DUPUYTREN CONTRACTURE; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 70349916617     PISSN: 09368051     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00402-008-0726-3     Document Type: Article

References (48)

1. Al-Qattan MM (2006) Factors in the pathogenesis of Dupuytren's contracture. J Hand Surg 31A:1527-1534
2. Augoff K, Ratajczak K, Gosk J, Tabola R, Rutowski R (2006) Gelatinase A activity in Dupuytren's disease. J Hand Surg 31A:1635-1639
3. Badalamente MA, Sampson SP, Hurst LC, Dowd A, Miyasaka K (1996) The role of transforming growth factor beta in Dupuytren's disease. J Hand Surg 21A:210-215
4. Badalamente MA, Hurst LC (1999) The biochemistry of Dupuytren's disease. Hand Clin 15:35-42
5. Badalamente MA, Hurst LC (2000) Enzyme injection as non-surgical treatment of Dupuytren's disease. J Hand Surg (Am) 25:629-636
6. Badalamente MA, Hurst LC (2007) Efficacy and safety of injectable mixed collagenases subtypes in the treatment of Dupuytren's contracture. J Hand Surg (Am) 32:767-774
7. Berndt A, Kosmehl H, Mandel U et al (1995) TGF beta and bFGF synthesis and localization in Dupuytren's disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin. Histochem J 27:1014-1020
8. Brenner P (2002) Dupuytren's disease of ring and little finger. Orthop Traumatol 10:138-158
9. Brew K, Dinakarpandian D, Nagase H (2002) Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochim Biophys Acta 1477:267
10. Brinckerhoff CE, Matrisian LM (2002) Matrix metalloproteinases: A tail of a frog that became a prince. Nat Rev Mol Cell Biol 3:207-214
11. Burge P, Hoy G, Regan P, Milne R (1997) Smoking, alcohol and the risk of Dupuytren's contracture. J Bone Joint Surg (Br) 79:206-210
12. Cordova A, Tripoli M, Corradino B, Napoli P, Moschella F (2005) Dupuytren's contracture: An update of biomolecular aspects and therapeutic perspectives. J Hand Surg (Br) 30(6):557-562
13. Forbes JM, Thallas V, Tomas MC et al (2003) The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 17:1762-1764
14. Hoegemann A, Wolfhard U, Kendoff D, Board TN, Olivier LC (2008) Results of total aponeurectomy for Dupuytren's contracture in 61 patients. A retrospective clinical study. Arch Orthop Trauma Surg, 31 May (Epub ahead of print)
15. Hurst LC, Badalamente MA (1999) Nonoperative treatment of Dupuytren's disease. Hand Clinics 15:97-107
16. Hutchinson JW, Tierney GM, Parsons SL, Davis TR (1998) Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J Bone Joint Surg 80B:907-908
17. Imai K, Hiramatsu A, Fukushima D, Pierschabacher D, Okada Y (1997) Degradation of decorin by matrix metalloproteinases: Identification of the cleavage sites, kinetic analyses and transforming growth factor-β1 release. Biochem J 322:809-814
18. Johnston P, Chojnowski AJ, Davidson RK et al (2007) A complete expression profile of matrix-degrading metalloproteinases in Dupuytren's disease. J Hand Surg (Am) 32:343-351
19. Kloen P (1999) New insights in the development of Dupuytren's contracture: A review. Br J Plast Surg 52:629-635
20. Luck JV (1959) Dupuytren's contracture: A new concept of the pathogenesis correlated with surgical management. J Bone Joint Surg (Am) 41:635-664
21. Massova I, Kotra LP, Fridman R, Mobashery S (1998) Matrix metalloproteinases: Structures, evolution, and diversification. FASEB J. 12:1075-1095
22. Mott JD, Werb Z (2004) Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 16:558-564
23. Moyer KE, Banducci DR, Graham WP 3rd, Ehrlich HP (2002) Dupuytren's disease: Physiologic changes in nodule and cord fibroblasts through aging in vitro. Plast Reconstr Surg 110:187-193
24. Murrell GAC, Francis MJO, Bromley L (1991) The collagen changes of Dupuytren's contracture. J Hand Surg (Br) 16:263-266
25. Nagase H, Woessner JF (1999) Matrix metalloproteinases. J Biol Chem 274:21491-21494
26. Nagase H, Visse R, Murphy G (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69:562-573
27. Pan D, Watson HK, Swigart C, Thomson JG, Honig SC, Narayan D (2003) Microarray gene analysis and expression profiles of Dupuytren's contracture. Ann Plast Surg 50:618-622
28. Patterson ML, Atkinson SJ, Knäuper V, Murphy G (2003) Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain. FEBS Lett 503:158-162
29. Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF (2004) Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology 64:399-404
30. Ramadori G, Knittel T, Saile B (1998) Fibrosis and altered matrix synthesis. Digestion 59:372-375
31. Ravanti L, Kahari VM (2000) Matrix metalloproteonases in wound repair. Int J Mol Med 6:391-407
32. Rayan GM (2007) Dupuytren disease: Anatomy, pathology, presentation, and treatment. J Bone Joint Surg (Am) 89:189-198
33. Reynolds JJ (1996) Collagenases and tissue inhibitors of metalloproteinases: A functional balance in tissue degradation. Oral Dis 2:70-76
34. Satish L, LaFramboise WA, O'Gorman DB et al (2008) Identification of differentially expressed genes in fibroblasts derived from patients with Dupuytren's contracture. BMC Med Genomics 1:10
35. Shaw RB, Chong AKS, Zhang A, Hentz VR, Chang J (2007) Dupuytren's disease: History, diagnosis, and treatment. Plast Reconstr Surg 120:44e-54e
36. Smeets R, Ulrich D, Unglaub F, Wöltje M, Pallua N (2008) Effect of regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. Int Wound J 5:195-203
37. Smith SP, Devaraj VS, Bunker TD (2001) The association between frozen shoulder and Dupuytren's disease. J Shoulder Elbow Surg 10:149-151
38. Starkweather KD, Lattuga S, Hurst LC et al (1996) Collagenase in the treatment of Dupuytren's disease: An in vitro study. J Hand Surg (Am) 21:490-495
39. Swartz WM, Lalonde DH (2008) MOC-PS SM CME Article: Dupuytren's disease. Plast Reconstr Surg 121:1-10
40. Tarlton JF, Meagher P, Brown RA, McGrouther DA, Bailey AJ, Afoke A (1998) Mechanical stress in vitro induces increased expression of MMPs 2 and 9 in excised Dupuytren's disease tissue. J Hand Surg 23B:297-302
41. Ulrich D, Hrynyschyn K, Pallua N (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinase in sera and tissue of patients with Dupuytren's disease. Plast Reconstr Surg 112:1279-1286
42. Ulrich D, Noah EM, von Heimburg D, Pallua N (2003) TIMP-1, MMP-2, MMP-9, and PIIINP as serum markers for skin fibrosis in patients following severe burn trauma. Plast Reconstr Surg 111:1423-1431
43. Ulrich D, Lichtenegger F, Eblenkamp M, Repper D, Pallua N (2004) Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with TRILUCENT breast implants. Plast Reconstr Surg 114:229-236
44. Unemori EN, Beck LS, Lee WP et al (1993) Human relaxin decreases collagen accumulation in vivo in two rodent models of fibrosis. J Invest Dermatol 101:280-285
45. Unemori EN, Pickford LB, Al Salles et al (1996) Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 98:2739-2745
46. Unglaub F, Loos B, Schwarz S, Kneser U, Dragu A, Horch RE (2008) Phlegmonous-infection in first degree Dupuytren's disease. Arch Orthop Trauma Surg, 20 March (Epub ehead of print)
47. Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 92:827-839
48. Vu TH, Werb Z (2000) Matrix metalloproteinases: Effectors of development and normal physiology. Genes Dev 14:2123-2133